PMID- 19656235
OWN - NLM
STAT- MEDLINE
DCOM- 20100824
LR  - 20221207
IS  - 1751-553X (Electronic)
IS  - 1751-5521 (Linking)
VI  - 32
IP  - 2
DP  - 2010 Apr
TI  - Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem 
      cells in Chinese patients with hematologic diseases.
PG  - 256-64
LID - 10.1111/j.1751-553X.2009.01181.x [doi]
AB  - Mesenchymal stem cells (MSCs) may be employed to support hematopoietic 
      reconstitution and mitigate graft-vs.-host disease (GVHD) in transplantation of 
      hematopoietic stem cells (HSCs). The aim of this study was to explore the 
      feasibility and safety of cotransplantation culture-expanded MSCs and HSCs from 
      the same human leukocyte antigen (HLA)-identical sibling donor in Chinese 
      patients with hematologic diseases. Bone marrow mononuclear cells from healthy 
      donors were cultured and expanded ex vivo. Immunophenotype, adipogenic and 
      osteogenic differentiation potential, and karyotype of the harvested MSCs were 
      detected on those who had been cotransplanted with HSCs and MSCs from the same 
      donor. Hematopoietic reconstitutions, complications, and clinical outcomes were 
      observed after cotransplantation in these patients. (1.77 +/- 0.40) x 10(6)/kg 
      (donor's weight) MSCs were successfully expanded from 23.6 +/- 5.96 ml of bone 
      marrow samples. They had normal karyotypes with bi-lineages differentiation 
      potential, and were CD73, CD90, and CD105 positive. Twelve patients underwent 
      cotransplantation with no observable adverse response during and after the 
      infusion of MSCs. Hematopoietic reconstitutions were rapid. Two patients 
      developed grade II-IV acute GVHD, and two extensive chronic GVHD. Four patients 
      suffered from cytomegalovirus infection but were cured eventually. Up to now, 
      seven patients have been followed as long as 29-57 months and five patients died. 
      It is concluded that MSCs can be expanded effectively by culture and it is safe 
      and feasible to cotransplant patients with allogenic culture-expanded MSCs and 
      HSCs.
FAU - Zhang, X
AU  - Zhang X
AD  - Department of Hematology, First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu Province, China.
FAU - Li, J-Y
AU  - Li JY
FAU - Cao, K
AU  - Cao K
FAU - Lu, H
AU  - Lu H
FAU - Hong, M
AU  - Hong M
FAU - Qian, S
AU  - Qian S
FAU - Wu, H
AU  - Wu H
FAU - Liu, P
AU  - Liu P
FAU - Xu, W
AU  - Xu W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090728
PL  - England
TA  - Int J Lab Hematol
JT  - International journal of laboratory hematology
JID - 101300213
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Asian People
MH  - Cells, Cultured
MH  - Female
MH  - Graft vs Host Disease/complications
MH  - *HLA Antigens
MH  - Hematologic Diseases/*therapy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Hematopoietic Stem Cells/*cytology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation/adverse effects
MH  - Mesenchymal Stem Cells/*cytology
MH  - Middle Aged
MH  - Siblings
EDAT- 2009/08/07 09:00
MHDA- 2010/08/25 06:00
CRDT- 2009/08/07 09:00
PHST- 2009/08/07 09:00 [entrez]
PHST- 2009/08/07 09:00 [pubmed]
PHST- 2010/08/25 06:00 [medline]
AID - CLH1181 [pii]
AID - 10.1111/j.1751-553X.2009.01181.x [doi]
PST - ppublish
SO  - Int J Lab Hematol. 2010 Apr;32(2):256-64. doi: 10.1111/j.1751-553X.2009.01181.x. 
      Epub 2009 Jul 28.